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ABSTRACT
Introduction: To design and implement a
novel cloud-based digital platform that allows
psoriatic patients and researchers to engage in
the research process.
Methods: Citizen Pscientist (CP) was created by
the National Psoriasis Foundation (NPF) to
support and educate the global psoriatic disease
community, where patients and researchers
have the ability to analyze data. Psoriatic
patients were invited to enroll in CP and con-
tribute health data to a cloud database by
responding to a 59-question online survey.
They were then invited to perform their own
analyses of the data using built-in visualization
tools allowing for the creation of ‘‘discovery
charts.’’ These charts were posted on the CP
website allowing for further discussion.
Results: As of May 2017, 3534 patients have
enrolled in CP and have collectively con-
tributed over 200,000 data points on their
health status. Patients posted 70 discovery
charts, generating 209 discussion comments.
Conclusion: With the growing influence of the
internet and technology in society, medical
research can be enhanced by crowdsourcing
and online patient portals. Patient discovery
charts focused on the topics of psoriatic disease
demographics, clinical features, environmental
triggers, and quality of life. Patients noted that
the CP platform adds to their well-being and
allows them to express what research questions
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matter most to them in a direct and quantifiable
way. The implementation of CP is a successful
and novel method of allowing patients to
engage in research. Thus, CP is an important
tool to promote patient-centered psoriatic dis-
ease research.
Keywords: Clinical research; Digital; Psoriasis;
Internet; Patient-reported outcomes; Online;
Portal; Psoriatic arthritis; Quality of life;
Symptoms
INTRODUCTION
Psoriasis is a common chronic autoimmune and
inflammatory disease that affects the skin and
causes a significant impact on quality of life,
affecting approximately 2–4% of the US popu-
lation [1, 2]. It is characterized by sharply
demarcated, scaly, and erythematous skin
lesions most commonly affecting the scalp,
elbows, knees, feet, and trunk. Psoriatic arthritis
(PsA), depression, anxiety, physical inactivity,
and social isolation may also develop, which
contribute further to the social stigma and
burden caused by psoriasis [3–5]. Psoriasis is also
strongly associated with diabetes and major
cardiovascular events, with excess mortality
seen in patients with psoriasis affecting 10% or
more of the body surface area [6–9]. An impor-
tant aspect of managing psoriatic disease is to
address the psychosocial and physical symp-
toms through support, in which patients often
benefit from sharing their experiences with a
community of psoriatic patients [3, 5].
Traditionally, patients have not been inclu-
ded in contributing to research design and
analysis because of under-recognition of the
value of their contributions as research partners
[10, 11]. There is a broader challenge of engag-
ing patients in research that includes the lack of
patient expertise or involvement. If only the
perspective of researchers is represented, topics
of less importance to patients may be explored,
thus providing results that are of limited use.
Given increasing social media utilization and
the proportion of adults that seek health infor-
mation from the internet, online crowd-
sourcing platforms have become innovative
tools that actively engage patients in the
research process [12–14]. Crowdsourcing solicits
creative ideas from paid consumers who com-
plete a requested task. Although crowdsourcing
in its most general sense involves non-selective
participation, a major advantage of disease-
specific portals is their potential for optimiza-
tion of patient groups that have different needs
than the general population [15–18].
There are several online portals that invite
patients to participate in the research process by
contributing health data or ideas and observing
the participants’ results (Table 1). Patient-
sLikeMe allows patients to share information
about their disease with other participants and
companies to develop improved healthcare
tools or services, in which 5789 psoriasis
patients are registered [19, 20]. However, data is
outsourced to partner pharmaceutical and
clinical trials research companies, which some
patients may not feel comfortable with [21].
The Global Parents for Eczema Research ana-
lyzed ‘‘patient and caregiver chatter’’ from social
networks for atopic dermatitis (AD), identifying
topics on topical treatments, the side effects of
steroids, and diet [22]. CureTogether, a website
with patient-generated symptom and treatment
data on skin diseases, was created in order to
diversify participants and increase participation
and has 335 enrolled psoriasis patients [23, 24].
Similarly, Citizen Pscientist (CP) was devel-
oped as a method of support and education for
the psoriatic disease community. However, CP
is distinct from any other crowdsourced projects
in that patients are directly involved in their
own research as both data contributors and
research analysts. The CP research project was
created in 2015 by the National Psoriasis
Foundation (NPF) and funded through a Pipe-
line-to-Proposal Award from a US non-profit
organization, the PCORI [25]. The objective of
CP is to engage psoriasis patients in the research
process, as the role of both subjects and ‘‘psci-
entists.’’ The initiation and implementation of
CP were overseen by a CP governing council of
patients, psoriatic disease researchers, and NPF
staff. Here, we describe a novel approach of
patient-driven research and share the experi-
ence of implementing a psoriatic disease-speci-
fic interactive patient database through CP.
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METHODS
CP Structure and Survey
A CP governing council, composed of patients,
researchers, and NPF staff generated 59 initial
survey questions asking about health data on
demographics, family history, symptoms, dis-
ease onset, psoriasis subtypes, disease severity,
triggers, quality of life, associated co-morbidi-
ties, and response to interventions. The CP
survey followed the Checklist for Reporting
Results of Internet E-Surveys (CHERRIES)
reporting criteria [26].
Patient Recruitment and Enrollment
Patients were invited to enroll in CP through a
website (www.citizenpscientist.org) promoted
by NPF. Individuals registered on the CP portal
with a valid e-mail address, which allowed for
the establishment of a single user profile. Elec-
tronic informed consent was obtained from all
participants at enrollment.
Recruitment was conducted through NPF’s
patient membership listserve, main website,
social media outlets, the Patient Navigation
Center, Psoriasis Advance magazine, and pro-
motional materials used at NPF in-person
events. The NPF currently has a strong social
media presence for adequate marketing poten-
tial, as demonstrated by 71,190 ‘‘likes’’ and
68,054 followers on Facebook, 19,700 followers
on Twitter, and 2180 followers on Linked-In.
Patient-Generated Data
CP’s most unique aspect allows patients to
explore de-identified patient-generated data
and examine the relationship between any two
variables from the intake survey. Such findings
are posted as charts on the website, which are
named ‘‘discovery charts.’’ After the results are
posted online, any of the users can comment on
the output. The features of openly publishing
results to the CP community promote further
explorations or allow patients to discuss or
relate the findings to their own experiences or
knowledge about their condition. Researchers,T
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such as those at academic universities, are also
able to analyze the data (Fig. 1).
The content of new survey questions can be
informed by patient input. The CP governing
council previously published on patient priori-
ties for comparative effectiveness research (CER)
within the CP community and our survey
reflects these topics of importance identified by
patients [27].
Data Analysis
Patient demographics and clinical characteris-
tics were tabulated by frequency using Micro-
soft Excel and STATA Special Edition, version
14.2 (College Station, TX). Geographical data
was analyzed using ArcGIS Online mapping
software (Environmental Systems Research
Institute, Redlands, CA, USA). All patient-gen-
erated discovery charts up to September 2017
were analyzed for the content of topics. Missing
data were included in the analysis and were
specified as ‘‘no response’’ in the results table.
Compliance with Ethics Guidelines
Institutional review board (IRB) approval for CP
was obtained from Genetic Alliance, which
includes patients outside of the USA.
RESULTS
Patient Participation
As of May 2017, there were 3534 users on the CP
platform contributing over 200,000 data points.
CP members were well distributed geographi-
cally in the USA; there were members from
every state and territory (Fig. 2). Globally, CP
members were primarily from the USA, UK,
France, India, and Australia (Fig. 3). CP mem-
bers were also observed from Fiji, Samoa, New
Zealand, Iceland, Saudi Arabia, Singapore, Tai-
pei, Finland, Syria, Greece, Austria, Russia, the
Caribbean, and South Africa, among others.
The activity of CP users over time is moni-
tored. Unique visits to the site averaged 800 per
month from May to December 2017 for a total
of 6409 visits by CP users, and the highest
activity was in July and August.
Patient Demographics
At baseline, 3246 (91.9%) reported having
physician-diagnosed psoriasis and 1545 (43.7%)
reported having physician-diagnosed psoriatic
arthritis (Table 2). A small percentage of CP
users (8.1%) did not specify psoriasis status. The
majority of CP users are greater than 40 years of
age; few users of the CP platform are below the
age of 18 (1.6%). There is a female predomi-
nance (60.9%) among the CP community with
male members only representing approximately
27.3%, though 11.8% did not answer data on
sex. The racial background of the CP commu-
nity was determined from questions on parental
ancestry rather than self-report of ethnicity. The
CP membership is predominantly White/Cau-
casian (69.6%), followed by Asian (4.9%),
Fig. 1 Workflow process of Citizen Pscientist. The CP
Governing Council helps develop survey questions, which
the CP patients answer. This data is then stored in a de-
identified cloud database. Then, CP patients and the
psoriatic research community can analyze the data, post
discoveries, and generate discussion about the findings.
These activities inform future survey questions and CP
initiatives
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Hispanic/Latino (4.5%), American Indian/Alas-
kan Native (3.4%), Black/African American
(1.7%), and Native Hawaiian/Pacific Islander
(0.3%).
Approximately 38% of CP users do not con-
sume alcohol, while a similar proportion report
having six drinks or less in 1 week and a
minority consumes more than seven drinks per
Fig. 2 Geographical distribution of CP users in the USA, October 2017
Fig. 3 Worldwide geographical distribution of CP users, October 2017, n = 3404
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week (11%). The majority of CP users (67%) do
not smoke, with 12.2% smoking one or more
cigarettes per day. Regarding family history,
36.7% of the CP users report an immediate
family member with psoriasis and 26.1% report
an immediate family member with psoriatic
arthritis.
Clinical Characteristics
It is well known from the literature that psori-
atic disease patients have an increased risk of
cardiovascular and autoimmune diseases
[7, 28–32]. The most frequently reported
comorbidities among the CP users include high
blood pressure (22.4%), high cholesterol
(20.1%), high triglycerides (9.6%), sleep apnea
(10.1%), thyroid disease (11.2%), and eczema/
atopic dermatitis (12.2%) (Table 3). Approxi-
mately 20% of CP users report having an
autoimmune-related comorbidity. One-fifth of
CP users did not report any of the listed
comorbid conditions.
Psoriasis may be divided into several clinical
subtypes. The majority of CP users reported
Table 2 Demographics of CP members, May 2017
Member characteristic Frequency,
n (%)
Disease
Psoriasisa 3246 (91.9)
Psoriasis with psoriatic arthritis 1545 (43.7)
No responsea 288 (8.1)
Agea
Under 18 56 (1.6)
18–30 383 (10.8)
31–40 541 (15.3)
41–50 699 (19.8)
51–65 1105 (31.3)
Over 65 354 (10.0)
No response 396 (11.2)
Genderb
Female 2151 (60.9)
Male 964 (27.3)
No response 419 (11.8)
Racial/ethnic background*,b
White/Caucasian 4918 (69.6)
Asian 346 (4.9)
Hispanic/Latino 317 (4.5)
American Indian/Alaskan Native 242 (3.4)
Black/African American 122 (1.7)
Native Hawaiian/Pacific Islander 19 (0.3)
Other 1253 (17.7)
No response 979 (13.9)
Alcohol consumption (drinks per week)
1–3 972 (27.5)
4–6 295 (8.3)
7–9 191 (5.4)
10 or more 191 (5.4)
I don’t drink 1338 (37.9)
No response 547 (15.4)
Table 2 continued
Member characteristic Frequency,
n (%)
Smoking (cigarettes per day)
1–10 208 (5.9)
11–20 167 (4.7)
[ 20 57 (1.6)
Not daily smoker 179 (5.1)
Non-smoker 2365 (67.0)
No response 558 (15.8)
Immediate family with psoriasisa 1296 (36.7)
Immediate family with psoriatic
arthritisa
921 (26.1)
*Total sum[ 100% because of multiple responses by
subjects
a Calculated using total number of subjects (n = 3534)
b Calculated using ethnic data from both mother and
father (n = 7068)
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Table 3 Clinical characteristics of CP members, May
2017
Member characteristic Frequency, n (%)
Comorbidities*,a
High blood pressure 790 (22.4)
High cholesterol 709 (20.1)
Thyroid disease 396 (11.2)
Sleep apnea 357 (10.1)
High triglycerides 341 (9.6)
Eczema/atopic dermatitis 431 (12.2)
Type 2 diabetes mellitus 193 (5.5)
Fatty liver disease 159 (4.5)
Cancer 144 (4.1)
Rheumatoid arthritis 136 (3.8)
Coronary artery disease 87 (2.5)
Uveitis 74 (2.1)
Sjo¨gren’s syndrome 60 (1.7)
Liver disease 48 (1.4)
Celiac disease 49 (1.4)
Crohn disease 44 (1.2)
Stroke 43 (1.2)
Alopecia areata 31 (0.9)
Lupus 27 (0.8)
Type 1 diabetes mellitus 21 (0.6)
Multiple sclerosis 15 (0.4)
Cutaneous T cell lymphoma 4 (0.1)
Parkinson’s disease 5 (0.1)
Other 220 (6.2)
None 675 (19.1)
No response 349 (9.9)
Psoriasis subtype*,a
Plaque 2459 (69.6)
Guttate 573 (16.2)
Inverse 485 (13.7)
Pustular 350 (9.9)
Table 3 continued
Member characteristic Frequency, n (%)
Erythrodermic 116 (3.3)
Not sure 1 (\ 0.1)
No response 294 (8.3)
Psoriasis location*,a
Scalp 2100 (59.4)
Arm/legs 1948 (55.1)
Elbow/knees 1799 (50.9)
Ears 1521 (43.0)
Abdomen 1429 (40.4)
Nails 1173 (33.2)
Skin folds 1013 (28.7)
Face 932 (26.4)
Genitals 854 (24.2)
Palms of hands 584 (16.5)
Soles of feet 561 (15.9)
No response 227 (6.4)
Psoriasis severitya
Mild:\ 5% BSA 1303 (36.9)
Moderate: 5–10% BSA 1035 (29.3)
Severe:[ 10% BSA 540 (15.3)
No response 249 (18.6)
Affected joints in psoriatic arthritisb
Knuckles 823 (53.3)
Knees 815 (52.7)
Toes 709 (45.9)
Wrists 664 (43.0)
Spine 629 (40.7)
Ankles 618 (40.0)
Shoulders 581 (37.6)
Hips 559 (36.2)
Neck 546 (35.3)
Elbows 485 (31.4)
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having plaque psoriasis (69.6%), followed by
guttate (16.2%), inverse (13.7%), pustular
(9.9%), and erythrodermic (3.3%) variants. The
scalp, elbows/knees, and arms/legs were the
most frequently reported areas with psoriatic
involvement (59.4%), followed by the ears and
abdomen (43% and 40%, respectively). Psoriasis
located on the face, genitals, and skin folds was
in each case reported in about 25% of patients
while the palms and soles of the hands and feet
were reported among 17% of users. Approxi-
mately 33% of CP users report having nail pso-
riasis. In terms of psoriasis severity, 36.9% of the
CP community reported less than 5% body
surface area (BSA) involvement, 29.3% reported
5–10% BSA, and 15.3% reported greater than
10% BSA. Psoriatic arthritis most frequently
affected the knees and knuckles (53%) followed
by the toes, wrists, ankles, and spine (45%).
Participant-Generated Analysis
A unique aspect of CP is that users can analyze
their own data instantly online and share their
findings with other users to generate discus-
sions. As of June 2017, patients had posted 70
discovery charts generating 209 comments by
the CP community. To examine the content of
these patient-generated charts, a consecutive
subset of 31 charts were further analyzed. Dis-
covery charts were focused on demographics or
clinical features of psoriatic disease (35%),
environmental triggers (32%), and quality of
life (32%). The relationship of demographic
characteristics was often displayed according to
psoriasis severity, such as how smoking varies
among those with different psoriasis severity.
The discovery charts posted on clinical features
examined, for example, which areas of the body
were affected by psoriasis and which areas were
the most bothersome stratified by psoriatic
arthritis status (Fig. 4), and which areas corre-
lated with sleep disturbance. In addition, the
frequency of comorbidities was explored among
different patient subsets. The subtype of psori-
asis was compared to several variables, such as
current treatments.
The discovery charts that examined envi-
ronmental triggers focused on the seasonal
association of flares or flare triggers such as
stress, skin injury, or smoking. Alternatively,
exploration of exercise and meditation were
identified to reduce flares. The association
between stress reduction and psoriasis severity
was examined.
Quality of life was explored through several
discovery charts examining activities that are
prevented by psoriatic arthritis. The association
between self-consciousness and gender was
examined, as well as discussions of overall life
satisfaction.
DISCUSSION
CP is a powerful tool that empowers the psori-
atic disease community by allowing patients to
take ownership in learning more about their
disease and to contribute back through self-di-
rected research. Though there have been several
other disease portals that rely on crowdsourcing
and online forums, CP is the only one that
promotes direct analysis of data by the users and
openly displays this information for rapid
patient-directed education and support.
Since CP attracts motivated patients who
enroll and provide data through an online
interface, it is expected that certain groups may
be over-represented. Indeed, we observed a rel-
atively high proportion of patients with psori-
atic arthritis (43.7%), which is toward the upper
limit of an estimated range of 7–48% seen in
epidemiologic studies and is higher than pop-
ulation-based estimates of approximately 10%
[33–37]. This indicates that individuals suffering
from psoriatic arthritis may be more motivated
to enroll in CP or that patients with more severe
Table 3 continued
Member characteristic Frequency, n (%)
Jaw 241 (15.6)
No response 5 (0.4)
BSA body surface area
*Total sum[ 100% due to multiple responses by subjects
a Calculated using total number of subjects (n = 3534)
b Calculated using total number of subjects having psori-
atic arthritis (n = 1545)
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disease (in which the prevalence of PsA is
increased) are more motivated to enroll. Simi-
larly, we observed a higher proportion of female
patients, whereas large-scale epidemiological
studies have found no clear gender predilection
for psoriasis [2, 38]. Our results are consistent
with the observation that women more often
than men engage in health information-seeking
behaviors [39].
The ages of CP participants follow a skewed
distribution favoring ages above 41. Interest-
ingly, the majority of participants are between
51 and 65 years (31.3%). The current CP com-
munity has a relatively low number of
minorities, possibly reflecting our advertising
that was limited to NPF members. Though
questions about socioeconomic status were not
asked in the CP survey, the NPF membership
from which the CP individuals were drawn from
are typically of a higher educational and
income status than the general population.
Approximately 17% of CP users reported cur-
rent smoking behaviors, which is slightly
greater than smokers found from US population
studies. According to the Centers for Disease
Control and Prevention, 13.6% of women in
the USA smoked compared to 16.7% of men in
2015 [40]. A study analyzing data from the
Fig. 4 Patient-generated analysis of most bothersome psoriasis sites. Screenshot from the CP online patient portal. Note the
diverse discussion and feedback from personal experiences
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Nurses’ Health Study, the Nurses’ Health Study
II, and the Health Professionals’ Follow-up
Study found that current or former smokers
were more likely to develop psoriasis than
nonsmokers and with increased smoking dura-
tion the risk for psoriasis increased [41].
Approximately 47% of the CP members report
alcohol consumption, with the majority con-
suming 1–3 drinks per week (27.5%) and only a
minority reporting greater than 10 drinks per
week (5.4%). Alcohol abuse has been associated
with a greater risk for developing or worsening
psoriasis [42]. Overall, the low prevalence of
alcohol use among the CP community may be
due to the female predominance, as women are
less likely to be alcohol misusers [43], and that
patients who participate in the CP initiative
may be also less likely to engage in alcohol
consumption. Within the CP community, 37%
of members reported at least one immediate
family member with psoriasis. This is consistent
with studies showing that approximately 40%
of patients with psoriasis or psoriatic arthritis
have a family history of these disorders in first-
degree relatives [44].
The high rate of disorders of impaired
metabolism among the CP community is con-
sistent with previous studies demonstrating a
greater likelihood of obesity, hypertension,
hypertriglyceridemia, hypercholesterolemia,
diabetes, and sleep apnea [45–51]. In addition,
20% of CP users reported an autoimmune-re-
lated comorbidity consistent with prior studies
detecting an increased autoimmune disease
prevalence among patients with psoriasis and
PsA such as uveitis, alopecia areata, celiac dis-
ease, systemic sclerosis, and Crohn disease
[32, 52, 53].
The type, severity, and location of psoriasis
reported among the CP users are parallel to
findings in the literature, with the exception of
pustular psoriasis occurring twice higher than
expected. Chronic plaque psoriasis is the most
common variant of psoriasis with the literature
reporting 55–79% of patients with psoriasis
identified as the plaque type [54, 55]. The
majority of CP patients with psoriasis have
moderate to severe disease, while population-
based estimates have suggested that about 20%
have moderate to severe psoriatic disease [56].
The most common areas include the scalp,
elbows or knees, and gluteal cleft. Psoriatic
arthritis has several different patterns of joint
involvement [57], and we also found a wide
distribution of joint involvement among CP
users with psoriatic arthritis, the most common
areas being the knuckles, knees, toes, wrists,
spine, and ankles.
The patient-centered discoveries of CP add
value to psoriasis knowledge by showing what
patients consider important about their disease.
The current literature is sparse for these high-
priority topics identified by psoriasis patients.
There are six studies that discuss environmental
triggers of psoriasis [58–63], while 10 articles
explore the seasonality of psoriasis [64–73].
These articles do not provide clear answers, may
be resource-intensive to develop, and might
have limited quality in the setting of con-
founding variables. Thus, there is an opportu-
nity for the CP platform to fill these gaps of
highly prioritized topics for psoriasis patients.
CP may redirect researchers to focus on
studying disease factors that are the most
important to patients. Furthermore, CP’s influ-
ence on research has the potential for enabling
researchers and physicians to connect with
ongoing questions generated by patients. For
example, a survey that ranked the patient’s top
priority CER topics showed that the following
were the highest importance to CP patients:
comparing the effectiveness, safety, risk, and
costs of treatment; diet or remedies; and com-
munication or management strategies. Specifi-
cally, the most popular CER questions were
comparing biologics to methotrexate, treat-to-
target management for psoriasis, comparisons
of home versus office-based phototherapy, and
differences between scalp psoriasis treatment
formulations [27]. Although patient–physician
communication is important in determining
patient needs, direct feedback from CP is valu-
able information for guiding future research
efforts and patient care [74].
Another unique aspect of CP is that messages
can be posted by participants in response to the
displayed discovery charts, which may result in
further discussion and analysis. For example, a
data-driven discussion debated whether the
observed results had statistical significance. As a
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result of the high interest in the debated topic,
researchers may consider following up on the
discussion points raised by the users.
The initial efforts of CP were focused in the
USA, as recruitment was implemented through
the NPF. However, we were surprised by the
reach of the CP platform to countries outside of
the USA. As the number of international par-
ticipants continues to increase, we will translate
the survey to other languages. The fact that the
intake survey and CP website are in English and
from a US-based website may also contribute to
the limited diversity of the subjects in our
summarized results.
Additionally, the activity of CP by users has
remained high over time, with the most active
months during the Summer. The average of 800
visits per month and total unique visits of 6409
in 2017 suggest that users may be visiting the
site multiple times, as the visits exceed the total
count of registered CP users.
Psoriasis patients have expressed that CP
adds significant value to their view of research,
their general psoriasis knowledge, and their
well-being. One member stated that CP is
valuable because it gives patients the ability to
be part of the effort to find a cure. Even though
discussion groups and online forums are valu-
able in letting patients share their experiences
with others, CP is unique in that patients can
influence the direction of future research. It lets
researchers know what questions matter the
most to patients in a direct and quantifiable
way. In addition, patients stated that CP is
valuable because it lets them know
what other patients’ concerns are by means of
quantifiable information in the form of easy-to-
read and easy-to-understand charts and graphs.
They get an instant picture of other patients’
concerns and trends in the entire community’s
response to survey questions. Another CP
member shared the fact that awareness of
overlapping disease features between patients
refines patients’ understanding of psoriasis fur-
ther. Importantly, CP emphasizes to those liv-
ing with psoriasis that they are not alone.
Individuals can anonymously share their
toughest moments experiencing psoriasis,
which can be translated into impactful science.
Limitations
With this interactive data tool, however, there
is a risk of misinterpretation of the results by
the CP users. For example, a comment was
posted to a discovery chart stating that fizzy
drinks and sugar could help psoriasis, which
was the opposite interpretation of what the
results displayed. Future enhancements to the
platform could consider a dermatologist or
research moderator to help users understand
the results correctly. It is also possible that an
analysis led by patients could induce potential
conflicts of interests and biases that could
favor inaccurate but desired health outcomes.
Therefore, the CP discovery graphs must be
interpreted with caution.
Self-reported data may not provide accurate
information, especially when examining clini-
cal factors in comparison to deriving health
information from electronic health records.
However, more insight into patient priorities
and a wider variety of patients are reached
when mining CP crowdsourced data. A corre-
lation between self-administered scoring of
disease severity to physician-generated clinical
measures of psoriasis severity using the Psori-
asis Area Severity Index (PASI) has been
reported, although a review of patient-reported
outcomes determined that most do not assess
validity [75–77]. In our study, 91.9% of CP
enrollees reported a physician-made diagnosis
of psoriasis, but it is unclear if the remainder
received a diagnosis of psoriasis from a differ-
ent kind of provider or self-diagnosed their
condition.
To improve the reliability of CP patient-
generated data, a validation of the self-reported
diagnoses through a review of patient medical
records will be performed by CP researchers.
After 10% of our total CP patients are sampled
and consented, their physicians will be asked to
provide documentation of medical records that
support or refute a patient’s psoriasis diagnosis.
As more robust data is generated by CP, the NPF
researchers will conduct a more formal analysis
of summary data.
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CONCLUSIONS
CP is a unique research platform that encour-
ages meaningful data exchange for psoriatic
disease research. Other patient portals have
used crowdsourced research for science inno-
vation; however, none, to our knowledge, have
integrated patients into the research develop-
ment or analysis process. Patient-generated
analyses in CP have demonstrated interest in
demographics and clinical features of psoriasis,
followed by environmental triggers and sea-
sonality, indicating that the patient perspective
can help guide future research areas.
Future efforts to enhance CP will focus on
several areas. One priority is recruitment of a
more racially diverse population through com-
prehensive outreach methods. Another priority
is maintaining the engagement of users,
through new survey questions and by expand-
ing the interface to a mobile application. A
subset of the CP data is currently being vali-
dated with medical records to assess the accu-
racy and quality of the self-reported
information. Finally, the addition of real-time
activity, fitness tracking, and DNA or other
biospecimens may also be explored. In these
ways, CP can continue to contribute to patient-
centered research that improves the quality of
life of psoriatic patients globally.
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